| ID | Sequence | Length | GC content |
|---|---|---|---|
| lnc-ST6GALNAC6-1:2 | UUUACUGCUGGGUUGGCCCAAAUGGUGUGUCUUUCUGGGGGUGGUGACC… | 474 nt | 0.5844 |
| lnc-ST6GALNAC6-1:3 | AGAUGGAGAUGAUCCUUGACAGGUCUGGUGGCUGGUUCGGGGUCUACUG… | 2310 nt | 0.5671 |
| lnc-ST6GALNAC6-1:4 | CGGCCUGAGGAGCGCGGACCCCGGCGCUCGGCUCCCGGCGCCAUGUGAG… | 505 nt | 0.6396 |
| lnc-ST6GALNAC6-1:5 | GGGCCGCGGGGGGCCGGGCGCUCCCCGCCGGAGAUGAGGAAACUGAGGC… | 452 nt | 0.6261 |
| lnc-ST6GALNAC6-1:6 | AAUCGCCGGGGAUGGGGAUGGAUGCGGGUCCCCCGGCGGCACCCCUAGA… | 466 nt | 0.6373 |
| lnc-ST6GALNAC6-1:7 | CAGCGGCCCCGCCUCCAGCGCAUGCCCUACCACUACUACGAGCCCAAGG… | 1071 nt | 0.5994 |
| lnc-ST6GALNAC6-1:8 | GGAGGAGGCCAGCAGCUAGCCAUUGCACACUGGGGUGAUGGGUGGGGGC… | 464 nt | 0.5970 |
No relevant information is available at the moment.
A study in humans identified the lnc-ST6GALNAC6-1 as a component of a competing endogenous RNA network significantly associated with myocardial ischemia-reperfusion injury, where it presented a negative correlation with injury and was computationally predicted to be targeted by hsa-miR-15a and hsa-miR-214 [Liu et al. DOI:10.1111/jcmm.14163].